Treatment of High-risk Acute Lymphoblastic Leukemia With Precision Medicine
|
|
- Juliet Hood
- 5 years ago
- Views:
Transcription
1 Treatment of High-risk Acute Lymphoblastic Leukemia With Precision Medicine
2 Minimal Residual Leukemia Level: Independent Prognostic Indicator Leukemic cell Tumor burden Growth potential Drug resistance Microenvironment Drug resistance Host Age Pharmacogenomics Treatment response Therapy Drug dosage Drug interactions Campana D Curr Opin Hematol 2012;19:313-8
3 Clinical Application of MRD Measurement Predictive value of MRD depends on timing of measurement, leukemia subtype, and preceding and subsequent treatment. Negative MRD after exposure to only a few drugs during early remission induction (<2 weeks) confers outstanding outcome, and treatment intensity could be reduced in latter part of induction to decrease morbidity and mortality in these patients. All childhood cases require at least a course of reinduction or delayed intensification. Patients with TEL-AML or hyperdiploidy (56 to 67 chromosomes) and achieving early negative MRD status may receive low intensity postremission therapy subsequently. High level or persistent MRD after consolidation therapy denotes high risk of relapse. However, effective postremission therapy may cure certain patients without transplant, e.g., high-dose methotrexate for hyperdiploid>50 ALL, cyclophosphamide+cytarabine+mercaptopurine for early T-cell precursor ALL.
4 AIEOP-BFM-ALL 2000: Increased Relapse After Lowering Intensity of Delayed Intensification in Standard-risk Patients with Negative MRD After Remission Induction 4741 pediatric patients with standard-risk ALL and negative MRD on days 33 and 78 after the start of remission induction Randomized to receive standard protocol II (49 days) vs. protocol III (29 days with 30% less dexamethasone and 50% less vincristine, doxorubicin, and cyclophosphamide) for delayed reintensification The 4-year cumulative risk of relapse was 3.2%±0.7% and 6.3%±1.0% for patients treated with protocol II and protocol III, respectively (p=0.09) The 8-year DFS was 92.3%±1.2% and 89.2%±1.3% for patients treated with protocol II and protocol III (p=0.04), and the 8-year survival was 98.0%±0.6% and 96.1%±0.8%, respectively. Schrappe et al ASH
5 Among Patients with Negative Day 19 MRD, only t(12;21) and hyperdiploid >50 Cases Are Good Candidates for Treatment Reduction Leukemia Subtype No* EFS (%) Survival (%) Relapse (%) t(12;21)/(etv6-runx1) Hyperdiploidy > Other NCI standard-risk B-ALL t(1;19)/(tcf3-pbx1) T-ALL NCI high-risk B-ALL P=0.023 P=0.369 P=0.017 *Patients with negative MRD (<0.01%) on Day 19 Pui et al. Leukemia 2017;34:333-9
6 Driver Genetic Mutations Identified in All Patients with Acute Lymphoblastic Leukemia D DUX4 D / Pui, Mullighan et al. J Clin Oncol 2015;33: , Zhang et al. Nature Genet 2016;48:1481-9
7 Ph-like or BCR-ABL1-like ALL BCR-ABL1 (Ph+) ALL: Alteration of IKZF1 (IKAROS), poor outcome Ph-like ALL: gene expression profile similar to Ph+ ALL but BCR-ABL negative Alteration of IKZF1, poor outcome RNA-seq identified ABL1, JAK2, PDGFRB, EPOR rearrangements in 15 cases Ph-positive Ph-like Ph-like Den Boer Lancet Oncol 2009; Mullighan NEJM 2009; Roberts Cancer Cell 2012
8 Ph-like ALL According to Age Gene expression profiling of 1725 pediatric, adolescent and young adult B- ALL cases (St Jude, COG, Alliance, ECOG, CALGB, MDACC) Childhood SR Childhood HR Adolescent yrs Young adult yrs Total Ph+ 1.3% 4.1% 6.0% 23.0% Ph-like 10.8% 13.7% 21.1% 27.3% Roberts, NEJM 2014;371:1005
9 Prevalence of Ph-like ALL by Age Den Boer Lancet oncol 2009, Mullighan NEJM 2009, Roberts NEJM 2014, Roberts JCO 2016
10 Ph-like ALL in HOVON study 17% Ph-like ALL among 127 ALL patients aged 16 to 71 years. None of the 21 Ph-like ALL tested had fusions involving JAK2, ABL1, ABL2, PDGFRB, CSF1R, IL2RB, NTRK3, TSLP, or TYK2. Induction failure occurred in 29% Ph-like ALL vs 6% other B-ALL (P=0.003). The cumulative risk of relapse was highest and the event-free survival was lowest in Ph-like ALL. 1 of 5 Ph-like ALL patients treated with allogeneic transplant vs. 9 of 10 Ph-like ALL patients treated with chemotherapy relapsed. Boer T et al. Haematologica July :e261-e264
11 HOVON-18 & 37: Event-free Survival According to Genotypes Boer et al Haematologica 2015;100:e261
12 Ph-like ALL identified in two German reference laboratories 12.6% Ph-like ALL among 207 B-ALL patients years old. Ph-like ALL was associated with alterations of IKZF1, CRLF2, JAK2, BTG1 Ph-like ALL patients were less likely to attain molecular remission (33% vs. 79%, P=0.02), and had inferior 5-year survival (22% vs. 64%, P=0.006) compared to other B-ALL patients. Among Ph-like ALL patients, relapse occurred in only 1 of 4 attained molecular remission but in 7 of 8 without molecular remission (P=0.02); one of 3 transplanted patients remained in remission. Herold T et al. Haematologica 2017:102:130-8
13 Treatment Outcome of Ph-like ALL by Age Group Pui et al. Clin Lymphoma, Myeloma and Leuk ( in press)
14 Total XV: No difference in Event-free Survival Between Ph-like ALL and Other B-ALL Cases 88.4%±1.9% 86.6%±4.1% Other B-ALL (n=304) 90.0%±4.7% 81.7%±11.7% Ph-like ALL (n=40) Roberts & Pui et al J Clin Oncol 2014;32:
15 No Difference in EFS and Survival Between Ph-like ALL and other B-ALL By Risk Group With MRD-directed Treatment Risk Group Subtype No. %5-yr EFS % 5-yr Survival Low Standard Ph-like Other Ph-like Other ± 0 95 ± 2 89 ± 7 84 ± ± 0 98 ± 1 89 ± 7 93 ± 3 High Ph-like Other ± ± ± ± 11 Roberts & Pui et al J Clin Oncol 2014;32:
16 Frequency of Genetic Subtypes in Ph-like ALL by Age Group Pui et al. Clin Lymphoma, Myeloma and Leuk (in press)
17 Kinase Rearrangements and Therapeutic Targets in Ph-like ALL Mullighan et al, unpublished data
18 Comparisons of Gene Pathways Between Adult and Pediatric B-ALL Liu et al. EBioMedicine 2016;8:173-83
19 ZNF384-related Gene Fusions 4.0% pediatric and 7.3% adult B-ALL High frequency of CD10-negative phenotype compared to other B-ALL (19% vs 3% in pediatric and 16% vs 5% in adult). High frequency of expression of myeloid-associated antigens CD13 and CD33 compared to other B-ALL (12% vs 2% in pediatric and 13% vs 0% in adult) High expression of GATA3, CEBPA and CEBPB, and upregulation of JAK-STAT pathway Intermediate outcome: 5-year survival (75% vs 69% in other B- ALL among pediatric and 40% vs 30% among adult patients) Liu et al. EBioMedicine 2016;8:173-83
20 MEF2D-related Gene Fusions 3.5% pediatric and 6.8% adult B-ALL Pediatric patients tended to be older (median, 12.1 years) Pre-B immunophenotype Upregulation of pre-b-cell receptor signaling molecules but downregulation of JAK-STAT signaling pathway Poor outcome: 5-year survival (33 vs 71% in other B- ALL among pediatric and 16% vs 31% among adult patients) Liu et al. EBioMedicine 2016;8: MEF2D-BCL9 fusion found in 4 of 59 relapsed or refractory ALL patients, and was associated with older age (10 to 13 years), B-ALL, very early relapse, and very poor outcome (0% survival). Suzuki et al. J Clin Oncol 2016;34:
21 Overall Survival of Adult and Pediatric ALL by Genotype. Liu et al. EBioMedicine 2016;8:173-83
22 Early T-cell Precursor ALL Immature phenotype (CD1a-, CD5 dim/neg, CD8-, myeloid/stem cell +) Distinct gene expression profile Genomic instability; activating mutations of genes regulating cytokine receptor and RAS signaling; inactivating mutations of histone modifying genes Poor early response with high MRD level at the end of remission induction Coustan Smith et al Lancet Oncol 10:
23 Treatment outcome of Early T-cell Precursor ALL Protocol Phenotype Steroid Daunorubicin Cyclo/ara-C 5y-EFS 5y-OS AIEOP-BFM2000 non-etp Pred 60mg or dex 80.8% 92.0% 10 mg/m 2 25mg/m 2 x2 2 courses ETP 86.2% at 3y 86.2% at 3 y St. Jude Total XVI non-etp 86.4% 91.3% Pred 40mg/m 2 25mg/m 2 x2 1 course ETP 71.4% 85.7% UKALL2003 non-etp 84.6% 90.9% Dex 6mg/m 2 25mg/m 2 x4 2 courses Probable ETP 76.7% 82.4% non-etp 86.9% 92.0% COG AALL0434 near-etp Pred 60mg/m 2 25mg/m 2 x4 2 courses 84.4% 91.6% ETP 87.0% 93.0% Conter et al. Lancet Hematol 2016;3:e80-6; Wood et al, Blood 2014, 124: abst 1; Patrick et al, BJH 2014; 166:421-24
24 Overall Survival According to Genetic Abnormality Among Patients with Induction Failure Schrappe M et al. N Engl J Med 2012;366:
25 Hypodiploid ALL:EFS According to MRD at the End of Induction Mullighan & Pui Blood 2015 ;126:2196-9
26 Molecular Target Therapy in ALL Bhojwani & Pui Lancet Oncol 2013;14:e205-17
27 New Immunological Approaches to Treat ALL Bhojwani & Pui Lancet Oncol 2013;14:e205-17
28 Novel Therapies For B-ALL Under Investigation Molecular therapy: ABL1 tyrosine kinase inhibitors (dasatinib, bosutinib, ponatinib) for Ph + or Ph-like ALL with the ABL-class fusion; Bcl-2 inhibitors (venetoclax, navitoclax) for MLL-rearranged ALL; JAK inhibitor (ruxolitinib) for Ph-like or JAK-dependent ALL; bortezomib for refractory ALL Antibody therapy: anti-cd19 (blinatumomab, denintuzumab), anti-cd20 (ofatumumab, obinutuzumab), anti-cd22 (inotuzumab, moxetumomab) Cell therapy: CD19 CAR T cells, CD22 CAR T cells
29 Novel Therapies For T-ALL Under Investigation Molecular therapy: ABL1 tyrosine kinase inhibitors (dasatinib, bosutinib, ponatinib) for NUP-214-ABL1; Bcl- 2 inhibitors (venetoclax, navitoclax) for ETP; JAK inhibitor (ruxolitinib) for ETP or JAK-dependent ALL; bortezomib for refractory ALL; Notch inhibitor (LY ) for refractory ALL Antibody therapy: anti-cd38 (Daratumumab) for refractory ALL Cell therapy: CD7 CAR T cells for refractory ALL
30 Cellular- and Immuno-therapy for patients with MRD positive disease Chimeric antigen receptor T cells Phase I/II CTL019 (n=60) 56 (93%) CR; 52 (93%) MRD-negative Maude ASCO 2016 abst 3011 US Multicenter CTL019 (n=35) 20 (57%) CR; 18 (90%) MRD-negavie Maude ASH 2016 abst 2801 Blinatumomab (BITE) Phase I/II (n=70) 27 (39%) CR; 14 (52%) MRD negative Von Stackelberg JCO 2016;34:4381 Maude SL, NEJM 2014; Topp MS Lancet Oncol 2015
31 Phase I/II Study of Blinatumomab (anti-cd19) in Relapsed/Refractory Pediatric ALL Based on Phase I data (n=49), recommended dose for Phase II study was 5 µg/m2/day for 7 days followed by 15 µg/m2/day for 21 days. Among 70 patients treated with recommended dose, 27 (39%) achieved CR within the first two cycles, 14 (52%) of whom achieved MRD negative status. Grade 3 adverse events: anemia (36%), thrombocytopenia (21%), and hypokalemia (17%), and cytokine-release syndrome (5%). Two patients (3%) had grade 2 seizures. Von Stackelberg et al. J Clin Oncol 34:4381-9
32 Relapsed-free Survival of the 27 Completed Responders* *13 (48%) received subsequent transplant Von Stackelberg et al. J Clin Oncol 34:4381-9
33 Overall Survival: Blinatumomab vs. Standard Chemotherapy in Adults with Relapsed or Refractory ALL Kantarjian et al. N Engl J Med 2017;376:836-47
34 Overall Survival With or Without Censoring of Allogeneic Transplantation Following Blinatumomab Treatment in Patients with Relapsed or Refractory Ph+ ALL Progressed After TKI-based Therapy (including ponatanib in 51% of patients) 36% (16/45) patients achieved CR/CRh; 88% of responders achieved MRD-negative status; 7 responders proceeded to transplantation. Martinelli et al. J Clin Oncol 2017 March 29 [Epub ahead of print]
35 Duration of Remission in Adults with Relapsed/Refractory ALL: Inotuzumab (anti-cd22) vs. Standard Therapy Kantajian et al. N Engl J Med 2016;375:740-53
36 Hematological relapse-free survival after blinatumomab therapy in adults with B-ALL and persistent or recurrent MRD disease Gökbuget et al. Haematologica 2017 Jan 12 [Epub ahead of print]
37 Ponatinib Yielded Better Result than Dasatinib in Adults With New Diagnosed Ph+ ALL Treated with Hyper-CVAD Regimen Sasaki et al. Cancer 2016;122:3650-6
38 Rituximab improved outcome of Young Adults (18 to 59 Years) With CD20-positive, Ph-negative Newly Diagnosed B-ALL Maury S et al. N Engl J Med 2016;375:
39 Maude S
40 Schematic Representation of Chimeric Antigen Receptor (CAR) Structure Dai et al JNCI 2016;108:djv439
41 CAR T Cell Therapy for Refractory/Relapsed Pediatric ALL (N=30) We hope we can decrease the use of transplantation. Results confirmed by US multicenter trial (ENSIGN) and Global trial (ELIANA): 2016 ASH abstracts #2801 and #221 Maude AL et al, N Engl J Med 2014;371:
42 Overall Survival of 60 Patients Treated in Phase I/II CTL019 93% (56/60) achieved CR at day 28; MRD negative in 52 patients; 100% CNS remission 24 patients in continuous remission 1 year, 19 without further treatment; 7 proceeded to transplant Maude et al. ASCO Abstract 3011
43 CTL019: US Multicenter Trial in Pediatric Relapsed/Refractory ALL Of 35 patients enrolled, 29 (83%) infused (2 manufacturing failures, 4 deaths) CR achieved in 20/29 patients (69%) MRD negative CR achieved in 18/29 (62%) patients Maude et al ASH 2016 Abstract 2801
44 Global Registration Trial of CTL019 in Pediatric and Young Adults with Relapsed/Refractory ALL 57 patients enrolled (15 pending infusion) in 25 centers in US, Europe, Australia and Japan 34/42 (81%) patients were infused (3 manufacturing failures, 5 not infused due to death or adverse events) 24/29 patients (84%) reached day 28 achieved CR or CRi Grade 3/4 toxicities: 45% cytokine release syndrome, 21% neuropsychiatric events, 29% febrile neutropenia, 21% hypotension, 21% increased AST, 21% increased bilirubin Grupp et al 2016 ASH abstract #221
45 CAR T Cells Induced Durable CNS Remission in Children with B-ALL and CNS Involvement 15 patients had CNS 3 within 12 months of infusion (4 had CNS 2 and 2 had CNS 3 on day 1 of infusion) Several had ocular or brain parenchymal involvement on MRI; all had 1 to 6 CNS relapses and had prior CNS irradiation CAR T cells persistent in CSF in 98% of patients up to 12+ months 11 of 15 patients in CCR up to 2.5 years (4 bone marrow relapse) Grade 2/3 encephalopathy developed in 25% patients, not different from 29% of other patients treated with CAR T cells Maude SL 2016 J Clin Oncol 34, 2016 (Suppl; abstr 3011); Rheingold SR ASH 2015, abstract 3769
46 Cloforabine (40 mg/m 2 ) + Cyclophosphamide (440 mg/m 2 ) + Etoposide 100 mg/m 2 ) daily for 5 days in Chinese Children with Relapsed or Refractory ALL 13 patients with refractory disease at diagnosis or relapse; median prior regimens was 2 (range, 1 to 4) Among 9 B-ALL, 2 achieved CR, 2 CRi, and 1 PR, and among 4 T-ALL, 3 attained CR and 1 PR. Eight of 9 responders bridged to hematopoietic cell transplantation; 4 remained alive in remission. All patients had febrile neutropenia or sepsis, and 31% had grade 3 hepatoxicity Liu et al. Ann Hematol 2016;95:501-7
47 Survival After Bridging Therapy with Cloforabine + Cyclophosphamide + Etoposide to Transplant in Chinese Patients with Relapsed/ Refractory ALL Liu et al. Ann Hematol 2016;95:501-7
48 Clofarabine in Combination With Mitoxantrone, Etoposide, Asparaginase and Dexamethasone in Pediatric ALL in Early Relapse Escalating dose of clofarabine (25% increments from 20 to 40 mg/m 2 /day for 5 days) with fixed doses of mitoxantrone, etoposide, asparaginase and dexamethasone Maximal tolerated dose was 32 mg/m 2 in 19 evaluable patients Of 19 evaluable patients, 11 (58%) achieved CR, of whom 6 proceeded to transplant, and 5 were alive for 16+ to 39+ months Nelken et al. Pediatr Blood Cancer 2016;63:270-75
49 Overall Survival of the 19 Patients Treated with VANDEVOL Regimen Nelken et al. Pediatr Blood Cancer 2016;63:270-75
50 List of pharmacogenetic tests to move from research to clinical care TPMT---thiopurines CYP2D6 --- codeine, amitriptyline, ondansetron G6PD---rasburicase, Septra CYP2C9, VKORC1---warfarin CYP2C19---clopidogrel, voriconazole DPYD---5FU HLA-B* abacavir HLA-B* carbamazepine (Asians ancestry) HLA-B* phenytoin HLA-B* allopurinol UGT1A1---irinotecan NUDT thiopurines CEP vincristine
51 Germline Mutations and ALL Risk TP53 in 50% low-hypodiploid ALL Holmfeldt et al. Nat Genet 2013;45: PAX5 G183S mutations in familial ALL Shah et al. Nat Genet 2013;45: ETV6 mutations in familial thrombocytopenia and hematopoietic malignancy Zhang et al. Nat Genet 2015;47:180-5 Noetzli et al. Nat Genet 2015;47:535-8 Topka et al. PLOS Genet 2015;11:e Moriyama et al. Lancet Oncol, 2015;16:
52 Future Perspective of Precision Medicine Precision medicine should be based on leukemia characteristics, host pharmacogenetics, treatment response, and availability of targeted therapy. Conventional therapy will be gradually replaced by targeted therapy, including antibodies, kinase inhibitors, and cellular therapy.
The Future of Leukemia Therapy
The Future of Leukemia Therapy Total XV: Treatment Results 1 0.9 93.5%±1.1% 91.7%±4% Overall Survival 0.8 0.7 Probability 0.6 0.5 0.4 0.3 0.2 0.1 0 N=498 0 2 4 6 8 10 12 14 Years from Diagnosis Pui & Evans
More informationRisk Stratification in Childhood Leukemia
Risk Stratification in Childhood Leukemia Why is risk stratification important? Toxicities Deepa Bhojwani, MD May 11, 2018 To determine intensity of therapy - When to intensify therapy - When to de-intensify
More informationPAX5-JAK2 fusion in acute lymphoblastic leukaemia. Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne
PAX5-JAK2 fusion in acute lymphoblastic leukaemia Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne Case 12-year-old girl Diagnosed with BCP ALL in November 2015 Presenting WCC 35x10
More informationCase 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX
Case 1 Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME
More informationControversies in Hematology: Case-Based Discussion. Acute leukemia in Adolescents and Young adults October 2018, Chiang Mai Thailand
Controversies in Hematology: Case-Based Discussion Acute leukemia in Adolescents and Young adults 25-26 October 2018, Chiang Mai Thailand Associate Prof. Adisak Tantiworawit, MD Division of Hematology,
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationCurrent Strategies for Relapsed/Refractory ALL in AYAs and Adults: Where We Are Now
Current Strategies for Relapsed/Refractory ALL in AYAs and Adults: Where We Are Now Eunice S. Wang, MD Roswell Park Cancer Institute Buffalo, New York, United States Relapsed ALL Carries a Poor Prognosis
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationManagement of Acute Lymphoblastic Leukemia
Management of Acute Lymphoblastic Leukemia Joseph C. Alvarnas, MD City of Hope Comprehensive Cancer Center Acute Lymphoblastic Leukemia (ALL) Approximately 6,000 patients per year diagnosed with ALL 60%
More informationBCR ABL1 like ALL: molekuliniai mechanizmai ir klinikinė reikšmė. IKAROS delecija: molekulinė biologija, prognostinė reikšmė. ASH 2015 naujienos
BCR ABL1 like ALL: molekuliniai mechanizmai ir klinikinė reikšmė. IKAROS delecija: molekulinė biologija, prognostinė reikšmė. ASH 2015 naujienos Ph like ALL BCR ABL1 like acute lymphoblastic leukemia (ALL)
More informationRedefining Patient Care in Acute Lymphoblastic Leukemia: The Impact of Novel Antibody and Immune Technologies on Clinical Outcomes
CME Redefining Patient Care in Acute Lymphoblastic Leukemia: The Impact of Novel Antibody and Immune Technologies on Clinical Outcomes Course Director and Moderator Daniel J. DeAngelo, MD, PhD Harvard
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More informationCARs vs. BiTE in ALL. David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center
CARs vs. BiTE in ALL David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center Disclosure Information David L Porter Speaker and members of study
More informationANCO 2015: Treatment advances in acute leukemia
ANCO 2015: Treatment advances in acute leukemia Michaela Liedtke, MD Stanford, CA September 12, 2015!" Disclosures Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Steering Committee
More informationAcute Myeloid and Lymphoid Leukemias
Acute Myeloid and Lymphoid Leukemias Hugo F. Fernandez, MD Department of Malignant Hematology & Cellular Therapy Moffitt at Memorial Healthcare System April 29, 2018 15 th Annual Miami Cancer Meeting Objectives
More informationETP - Acute Lymphoblastic Leukaemia
ETP - Acute Lymphoblastic Leukaemia Dr Sally Campbell - Royal Children s Hospital Melbourne 24 February 2017 T-ALL 12-15% of all newly diagnosed ALL cases in pediatrics are T-ALL T-ALL behaves differently
More informationHandout for lecture on lymphoblastic neoplasms presented by Rob McKenna
Handout for lecture on lymphoblastic neoplasms presented by Rob McKenna The following slides represent a near final version of the presentation that will be given in Maui, January 23,2018. Minor changes
More informationImmunotherapies in Acute Lymphoblastic Leukaemia. Professor David Ritchie Royal Melbourne Hospital
Immunotherapies in Acute Lymphoblastic Leukaemia Professor David Ritchie Royal Melbourne Hospital Blinatumomab Cases Case 1: Mr BE 30 year old male Aged 17, diagnosed Philadelphia negative B-ALL in Nov
More informationElisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
Elisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria Incidence Diagnosis Prognostic factors Treatment Induction therapy - HSCT Indications for HSCT
More informationPediatric Treatment Approaches for Adolescent and Young Adult Acute Lymphoblastic Leukemia
Pediatric Treatment Approaches for Adolescent and Young Adult Acute Lymphoblastic Leukemia 2017 Texas Adolescent and Young Adult (TAYA) Oncology Conference Elizabeth Raetz, MD Acute Lymphoblastic Leukemia
More informationPh-like (BCR/ABL1-like): un apporoccio baato sul target molecolare
Ph-like (BCR/ABL1-like): un apporoccio baato sul target molecolare Sabina Chiaretti, MD PhD LE SFIDE DELLA MEDICINA DI PRECISIONE IN EMATOLOGIA Bologna 28 Giugno, 2018 Topics: BCR/ABL1-like and other subgroups
More informationAcute leukemia and myelodysplastic syndromes
11/01/2012 Post-ASH meeting 1 Acute leukemia and myelodysplastic syndromes Peter Vandenberghe Centrum Menselijke Erfelijkheid & Afdeling Hematologie, UZ Leuven 11/01/2012 Post-ASH meeting 2 1. Acute myeloid
More informationBest of ASH: Acute leukemia. Frédéric Baron
Best of ASH: Acute leukemia Frédéric Baron I Acute Myeloid Leukemia Flt3 inhibitors (ratify, sorafenib after HCT) 5 other important abstracts (in brief) Mutated genes in AML FLT3: The Cancer Genome Atlas
More informationBiTE in ALL and AML. Ibrahim Aldoss, MD Assistant Professor, City of Hope Hematology and Hematopoietic Cell Transplantation
BiTE in ALL and AML Ibrahim Aldoss, MD Assistant Professor, City of Hope Hematology and Hematopoietic Cell Transplantation Disclosure I am consultant for Helocyte and Speaker Bureau for JAZZ Immune system
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationTreatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago
Treatments and Current Research in Leukemia Richard A. Larson, MD University of Chicago 2 Acute (rapid progression) Myeloid Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Lymphoid Acute
More informationLeukemia. Roland B. Walter, MD PhD MS. Fred Hutchinson Cancer Research Center University of Washington
Leukemia Roland B. Walter, MD PhD MS Fred Hutchinson Cancer Research Center University of Washington Discussed Abstracts Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationFirst relapsed childhood ALL Role of chemotherapy
First relapsed childhood ALL Role of chemotherapy Thirachit Chotsampancharoen, M.D. Division of Pediatric Hematology/Oncology Department of Pediatrics Prince of Songkla University Hat-Yai, Songkhla 25
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationCARE at ASH 2014 Leukemia. Julie Bergeron, MD Maisonneuve-Rosemont Hospital
CARE at ASH 2014 Leukemia Julie Bergeron, MD Maisonneuve-Rosemont Hospital Acute Leukemias Dr. Julie Bergeron Hôpital Maisonneuve-Rosemont, Montréal Disclosures Advisory boards in 2014: AMGEN EUSA pharma
More informationSummary. Olga Zając, Katarzyna Derwich, Katarzyna Stefankiewicz, Jacek Wachowiak. Rep Pract Oncol Radiother, 2007; 12(5):
Rep Pract Oncol Radiother, 2007; 12(5): 283-288 Preliminary Communication Received: 2007.03.27 Accepted: 2007.07.24 Published: 2007.10.18 Authors Contribution: A Study Design B Data Collection C Statistical
More informationFuture Directions in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
Future Directions in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Heidi Trinkman, PharmD. Clinical Pharmacy Specialist Cook Children s Medical Center Fort Worth, Texas Disclosures Speaker s
More informationRelapsed acute lymphoblastic leukemia. Lymphoma Tumor Board. July 21, 2017
Relapsed acute lymphoblastic leukemia Lymphoma Tumor Board July 21, 2017 Diagnosis - Adult Acute Lymphoblastic Leukemia (ALL) Symptoms/signs include: Fever Increased risk of infection (especially bacterial
More informationStandard risk ALL (and its exceptions
Mahshid Mehdizadeh Standard risk ALL (and its exceptions WBC at diagnosis below 50 109/L - age 1 year - no central nervous system (CNS) involvement - ETV6/RUNX1 positivity - MRD at Day
More informationMRD in ALL: Correct interpretation in clinical practice. Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh
MRD in ALL: Correct interpretation in clinical practice Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh Minimal residual disease Subclinical level of residual leukemia Below
More informationDevelopment of Precision Medicine Therapies for Pediatric Acute Lymphoblastic Leukemia Korean Society of Hematology Meeting March 31, 2018
Development of Precision Medicine Therapies for Pediatric Acute Lymphoblastic Leukemia Korean Society of Hematology Meeting March 31, 2018 Stephen P. Hunger, M.D. Chief, Division of Pediatric Oncology
More informationInotuzumab Ozogamicin in ALL. Hagop Kantarjian M.D. May 2016 Bologna, Italy
Inotuzumab Ozogamicin in ALL Hagop Kantarjian M.D. May 2016 Bologna, Italy Immuno Oncology in ALL Monoclonals + cytotoxic agents e.g.inotuzumab Bispecific monoclonals (CD3 + CD19) e.g.blinatumomab Modified
More informationEvolving Targeted Management of Acute Myeloid Leukemia
Evolving Targeted Management of Acute Myeloid Leukemia Jessica Altman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives Identify which mutations should be assessed
More informationThe use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia
NOVEL APPROACHES TO ACUTE LYMPHOBLASTIC LEUKEMIA The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia Daniel J. DeAngelo 1 1 Harvard Medical School, Dana-Farber Cancer
More informationFAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated
Page 1 of 8 COG-AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like
More informationTargeting CD20 and CD22 in B-cell ALL Daniel J. DeAngelo, MD, PhD
Targeting CD20 and CD22 in B-cell ALL Daniel J. DeAngelo, MD, PhD Harvard/Dana-Farber Cancer Institute Boston, MA Disclosures for Daniel J. DeAngelo, MD, PhD Royalty Receipt of intellectual property/ Patent
More informationCAALL-F01 OVERVIEW, OUTLINES COMITE LEUCEMIES 19 NOVEMBRE 2015
CAALL-F01 OVERVIEW, OUTLINES COMITE LEUCEMIES 19 NOVEMBRE 2015 Current outcomes in childhood and adolescent ALL: FRALLE 2000 protocol: 2176 pts; 1-20 years FRALLE Group Event-Free Overall Survival Survival
More informationNew concepts in the management of elderly patients with AML
New concepts in the management of elderly patients with AML Martha L. Arellano, MD Associate Professor of Hematology/Oncology Director, Hematology & Medical Oncology Fellowship Program Winship Cancer Institute
More informationSummary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, San Diego CA
Summary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, 2016 - San Diego CA ASH 2016 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://ash.confex.com/ash/2016/webprogram/start.html
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
Single Technology Appraisal (STA) Tisagenlecleucel-T for previously treated B-cell acute lymphoblastic Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationTreatment of Adult Acute Lymphoblastic Leukemia (ALL) With a
Focus on Emerging Investigational and Targeted Therapies Review Article [1] September 12, 2012 By Michael S. Mathisen, PharmD [2], Elias Jabbour, MD [3], and Hagop M. Kantarjian, MD [4] In this review,
More informationCURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of )
Leukemia AALL0932 closed after Induction CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 10.10.2017) Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized
More informationDr Shankara Paneesha. ASH Highlights Department of Haematology & Stem cell Transplantation
ASH Highlights 2015 Themes of ASH 2015 Novel therapies - Myeloma AML Lymphoma Pd-L1 & PD-l inhibitors Emerging concepts in biology HIF-1a pathway Cautionary tales ASH Choosing Wisely list IFM/DFCI
More informationObjectives. Emily Whitehead 10/11/2018. Chimeric Antigen Recepetor T-Cells (CAR-T) CAR-T Therapy: The Past, The Present, and The Future
Objectives CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Review indications for FDA approved CAR-T therapy
More informationPhiladelphia chromosome-positive acute lymphoblastic leukemia in childhood
Review article DOI: 10.3345/kjp.2011.54.3.106 Korean J Pediatr 2011;54(3):106-110 Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood Hong Hoe Koo, M.D., Ph.D. Department of Pediatrics,
More informationCAR-T Therapy: The Past, The Present, and The Future. Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center
CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Objectives Review indications for FDA approved CAR-T therapy
More informationPacharapan Surapolchai, MD Associate Professor Department of Pediatrics, Faculty of Medicine, Thammasat University, Thailand October 2018
Pacharapan Surapolchai, MD Associate Professor Department of Pediatrics, Faculty of Medicine, Thammasat University, Thailand October 2018 Outline Case study Introduction of Current management of infantile
More informationClinical Guidelines for Lymphoid Diseases Acute Lymphoblastic Leukaemia (ALL)
Clinical Guidelines for Lymphoid Diseases Acute Lymphoblastic Leukaemia (ALL) Reference Number Version Status Executive Lead(s) Name and Job Title Author(s) Name and Job Title 13-2H-107 8 Dr Helen Barker
More informationPharmacotherapy for adult acute lymphoblastic leukemia: an update from recent clinical trials and future directions
Pharmacotherapy for adult acute lymphoblastic leukemia: an update from recent clinical trials and future directions Clin. Invest. (2012) 2(7), 715 731 In adults, acute lymphoblastic leukemia (ALL) is an
More informationProphylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010
Prophylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010 Outline Epidemiology Risk-groups Background & Rationale
More informationCan ALL be managed without chemotherapy/transplant? (Position: NO) D.Hoelzer J.W.Goethe University Frankfurt
Can ALL be managed without chemotherapy/transplant? (Position: NO) D.Hoelzer J.W.Goethe University Frankfurt Barcelona, September 2012 First report of Monotherapy in childhood ALL 10/16 children with acute
More informationPediatric Acute Lymphoblastic Leukemia. Highlights of ASH 2015
Pediatric Acute Lymphoblastic Leukemia Highlights of ASH 2015 Thai National Protocol Outcomes Outcome is very dependent on treatment Patient s compliance Treatment of ALL Induction Intensification Maintenance
More informationPrognostic significance of leukopenia in childhood acute lymphoblastic leukemia
ONCOLOGY LETTERS 7: 1169-1174, 2014 Prognostic significance of leukopenia in childhood acute lymphoblastic leukemia YUSUKE SHIOZAWA 1, JUNKO TAKITA 1,2, MOTOHIRO KATO 3, MANABU SOTOMATSU 4, KATSUYOSHI
More informationPhiladelphia-positive Acute Lymphoblastic Leukemia
Philadelphia-positive Acute Lymphoblastic Leukemia Nicolas Boissel Service d Hématologie Unité Adolescents et Jeunes Adultes Hôpital Saint-Louis, Paris Ph+ acute lymphoblastic leukemia DR+, CD19+, CD22+,
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Biondi A, Schrappe M, De Lorenzo P, et al.
More informationAML Emerging Treatment Strategies
Welcome and Introduction Clare Karten, MS Senior Director, Mission Education The Leukemia & Lymphoma Society AML Emerging Treatment Strategies Wendy Stock, MD Professor of Medicine, Section of Hematology/Oncology
More informationPh-like acute lymphoblastic leukemia
OPTIMIZING TREATMENTS FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA: WHAT IT TAKES TO MOVE THE NEEDLE Ph-like acute lymphoblastic leukemia Thai Hoa Tran 1 and Mignon L. Loh 1,2 1 Helen Diller Family Comprehensive
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationReference: NHS England 1602
Clinical Commissioning Policy Proposition: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation Reference: NHS England 1602 First published: TBC
More informationADVANCES IN CHILDHOOD ACUTE LEUKEMIAS : GENERAL OVERVIEW
ADVANCES IN CHILDHOOD ACUTE LEUKEMIAS : GENERAL OVERVIEW Danièle SOMMELET European Scientific Seminar Luxemburg, 3.11.2009 1 Definition of acute leukemias Malignant process coming from lymphoid (85 %)
More informationTCF3 breakpoints of TCF3-PBX1 (patients 1a 5a) and TCF3-HLF (patients 6a 9a and11a) translocations.
Supplementary Figure 1 TCF3 breakpoints of TCF3-PBX1 (patients 1a 5a) and TCF3-HLF (patients 6a 9a and11a) translocations. The CpG motifs closest to the breakpoints are highlighted in red boxes and the
More informationHow Do You Measure Success in ALL?: Assessment of MRD
How Do You Measure Success in ALL?: Assessment of MD Martin Schrappe, MD, PhD University Medical Center Schleswig-Holstein Christian-Albrechts-University Kiel, Germany Topics Current risk classification
More informationHighlights from the 2017 Annual Meeting of the American Society of Hematology
Latest NEWS IN BLOOD CANCER RESEARCH Highlights from the 2017 Annual Meeting of the American Society of Hematology CancerCare Connect Booklet Series www.cancercare.org The CancerCare Connect Booklet Series
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Blinatumomab (Blincyto) for Pediatric Acute Lymphoblastic Leukemia August 23, 2017
pan-canadian Oncology Drug Review Final Clinical Guidance Report Blinatumomab (Blincyto) for Pediatric Acute Lymphoblastic Leukemia August 23, 2017 DISCLAIMER Not a Substitute for Professional Advice This
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationRemission induction in acute myeloid leukemia
Int J Hematol (2012) 96:164 170 DOI 10.1007/s12185-012-1121-y PROGRESS IN HEMATOLOGY How to improve the outcome of adult acute myeloid leukemia? Remission induction in acute myeloid leukemia Eytan M. Stein
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationANCO: ASCO Highlights 2018 Hematologic Malignancies
ANCO: ASCO Highlights 2018 Hematologic Malignancies Brian A. Jonas, M.D., Ph.D. UC Davis Comprehensive Cancer Center August 25, 2018 Brian Jonas, MD, PhD ANCO: ASCO Highlights 2018 Relevant financial relationships
More informationApplying Chimeric Antigen Receptor T cells (CAR-T) to hematologic malignancies
Applying Chimeric Antigen Receptor T cells (CAR-T) to hematologic malignancies Anne W. Beaven, MD Associate Professor Duke University Medical Center Duke Debates April 21, 2017 Chimeric Antigen Receptor
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationKYMRIAH (tisagenlecleucel)
KYMRIAH (tisagenlecleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationCAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Identifying Appropriate Patients and Maximizing Outcomes. Shannon L.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Identifying Appropriate Patients and Maximizing Outcomes Shannon L. Maude, MD, PhD CTL019 cell Lentiviral vector Anti-CD19 CAR construct CD19 Native
More informationThe probability of curing children with acute. brief report
brief report Hematopoietic stem cell transplant versus chemotherapy plus tyrosine kinase inhibitor in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) Khadra
More informationUpdate in Acute Lymphoblastic Leukemia Richard M, Stone, M.D.
Update in Acute Lymphoblastic Leukemia Richard M, Stone, M.D. Director, Adult Leukemia Program Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School Boston, MA Disclosure Information
More informationTARGETED THERAPY FOR CHILDHOOD CANCERS
TARGETED THERAPY FOR CHILDHOOD CANCERS AZIZA SHAD, MD AMEY DISTINGUISHED PROFESSOR OF PEDIATRIC HEMATOLOGY ONCOLOGY, BLOOD AND MARROW TRANSPLANTATION LOMBARDI CANCER CENTER GEORGETOWN UNIVERSITY HOSPITAL
More informationAcute Lymphoblastic and Myeloid Leukemia
Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women
More informationACUTE LEUKEMIA. Zwi N. Berneman University of Antwerp & Antwerp University Hospital. 16th Post-ASH Meeting Zaventem, 10 January 2014
ACUTE LEUKEMIA Zwi N. Berneman University of Antwerp & Antwerp University Hospital 16th Post-ASH Meeting Zaventem, 10 January 2014 ACUTE MYELOID LEUKEMIA HIGH-RISK AML Clinically and biologically distinct
More informationAcute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia Danielle, ALL survivor Support for this publication provided by Revised 2016 Booklet Updates The Leukemia & Lymphoma Society wants you to have the most up-to-date information
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationObjectives. I do not have anything to disclose.
Treatment of APL Objectives I do not have anything to disclose. Objectives 1. Urgency of early recognition and treatment 2. Treatment based on risk stratification 3. Monitoring for relapse 4. Treatment
More informationKevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias
Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias Relevant financial relationships in the past twelve months by presenter or spouse/partner. Speakers bureau: Novartis, Janssen, Gilead, Bayer The
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationMANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS
MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS Introduction The management of ALL, the most common childhood malignancy (1/3 rd of all malignancy), has
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationManagement of Acute Lymphoblastic Leukemia in Young Adults
Management of Acute Lymphoblastic Leukemia in Young Adults Lori S. Muffly, MD, MS, Natalie Reizine, MD, and Wendy Stock, MD Dr Muffly is an Assistant Professor of Medicine Blood and Marrow Transplantation
More informationExploiting the Immune System: Chimeric Antigen Receptor-T Cell Therapy for Hematologic Malignancies
Exploiting the Immune System: Chimeric Antigen Receptor-T Cell Therapy for Hematologic Malignancies Maurice Alexander, PharmD, BCOP, CPP Clinical Specialist, Blood and Marrow Transplant UNC Bone Marrow
More informationTreatment Landscape in R/R DLBCL Novel Targets and Strategies. Wyndham H. Wilson, M.D., Ph.D. Senior Investigator
Treatment Landscape in R/R DLBCL Novel Targets and Strategies Wyndham H. Wilson, M.D., Ph.D. Senior Investigator Gene-expression profiling of DLBCL subtypes Roschewski, M. et al. (2013) Nat. Rev. Clin.
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationImproved outcome in childhood ALL with intensive consolidation and hematopoietic stem cell transplant
VOLUME 45 ㆍ NUMBER 2 ㆍ June 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Improved outcome in childhood ALL with intensive consolidation and hematopoietic stem cell transplant Jeong A Park 1,
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Blinatumomab (Blincyto) for Acute Lymphoblastic Leukemia February 4, 2016
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Blinatumomab (Blincyto) for Acute Lymphoblastic Leukemia February 4, 2016 DISCLAIMER Not a Substitute for Professional Advice This report
More informationTiming and complications of allogeneic stem cell transplant in Ph + ALL
Timing and complications of allogeneic stem cell transplant in Ph + ALL Dr Ashlea Campbell Haematology Advanced Trainee Concord Repatriation and General Hospital Royal Prince Alfred Hospital 24 th Feb
More information